Amy M Weise
Overview
Explore the profile of Amy M Weise including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
293
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gounder M, Bauer T, Schwartz G, Weise A, LoRusso P, Kumar P, et al.
J Clin Oncol
. 2023 Jan;
41(9):1714-1724.
PMID: 36669146
Purpose: This study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of milademetan, a small-molecule murine double minute-2 (MDM2) inhibitor, in patients with advanced cancers. Patients And Methods: In this...
2.
Tsimberidou A, Shaw J, Juric D, Verschraegen C, Weise A, Sarantopoulos J, et al.
J Hematol Oncol
. 2021 Aug;
14(1):127.
PMID: 34407844
Background: The PI3K/AKT/mTOR (PAM) pathway is a key regulator of tumor therapy resistance. We investigated M2698, an oral p70S6K/AKT dual inhibitor, in patients with advanced cancer who failed standard therapies....
3.
Fong L, Hotson A, Powderly J, Sznol M, Heist R, Choueiri T, et al.
Cancer Discov
. 2019 Nov;
10(1):40-53.
PMID: 31732494
Adenosine mediates immunosuppression within the tumor microenvironment through triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this pathway could be targeted as an immunotherapy, we performed a...
4.
Garrido-Laguna I, Krop I, Burris 3rd H, Hamilton E, Braiteh F, Weise A, et al.
Int J Cancer
. 2019 Jan;
145(7):1798-1808.
PMID: 30680712
PF-06647263, a novel antibody-drug conjugate consisting of an anti-EFNA4 antibody linked to a calicheamicin payload, has shown potent antitumor activity in human xenograft tumor models, including triple-negative breast cancer (TNBC)....
5.
Weise A, Gadgeel S
Lung Cancer (Auckl)
. 2017 Feb;
5:35-42.
PMID: 28210140
Non-small-cell lung cancer (NSCLC) is a heterogeneous disease and a challenging malignancy to treat, as many patients have advanced disease at the time of diagnosis. Recent advances have led to...
6.
Weise A, Flaherty L
Curr Oncol Rep
. 2014 Oct;
16(11):409.
PMID: 25286906
High-dose interferon is the current standard of care for the adjuvant treatment of high-risk cutaneous melanoma. Despite numerous clinical trials using interferon in a variety of doses and schedules, none...
7.
Salloum R, Liu C, Weise A
Am J Health Syst Pharm
. 2010 Dec;
68(1):43-6.
PMID: 21164064
Purpose: A possible case of levofloxacin-induced thrombocytopenia is reported. Summary: A 73-year-old Caucasian woman with stage IV squamous cell cancer of the oral cavity arrived at the hospital with a...
8.
Radkevich-Brown O, Piechocki M, Back J, Weise A, Pilon-Thomas S, Wei W
Cancer Immunol Immunother
. 2009 Sep;
59(3):409-17.
PMID: 19730859
In situ expression of a foreign antigen and an immune-modulating cytokine by intratumoral DNA electroporation was tested as a cancer therapy regimen. Transgene expression in the tumors was sustained for...
9.
Weise A, Liu C, Shields A
Ann Pharmacother
. 2009 Apr;
43(4):761-6.
PMID: 19336648
Objective: To report the occurrence of fatal acute liver failure following addition of levothyroxine to a regimen of sunitinib and acetaminophen. Case Summary: A 57-year-old woman who started sunitinib treatment...
10.
Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression
Fu J, Weise A, Falany J, Falany C, Thibodeau B, Miller F, et al.
Breast Cancer Res Treat
. 2009 Mar;
120(1):35-45.
PMID: 19308726
TaqMan Gene Expression assays were used to profile the mRNA expression of estrogen receptor (ERalpha and ERbeta) and estrogen metabolism enzymes including cytosolic sulfotransferases (SULT1E1, SULT1A1, SULT2A1, and SULT2B1), steroid...